Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, UK.
Nat Prod Rep. 2017 Jul 1;34(7):712-783. doi: 10.1039/c7np00010c. Epub 2017 Jun 26.
Covering: up to 2017The overwhelming majority of antibiotics in clinical use originate from Gram-positive Actinobacteria. In recent years, however, Gram-negative bacteria have become increasingly recognised as a rich yet underexplored source of novel antimicrobials, with the potential to combat the looming health threat posed by antibiotic resistance. In this article, we have compiled a comprehensive list of natural products with antimicrobial activity from Gram-negative bacteria, including information on their biosynthetic origin(s) and molecular target(s), where known. We also provide a detailed discussion of several unusual pathways for antibiotic biosynthesis in Gram-negative bacteria, serving to highlight the exceptional biocatalytic repertoire of this group of microorganisms.
截至 2017 年
临床使用的绝大多数抗生素都来源于革兰氏阳性放线菌。然而，近年来，革兰氏阴性菌已逐渐被公认为是新型抗菌药物的丰富但尚未充分开发的来源，具有对抗抗生素耐药性所构成的日益严重的健康威胁的潜力。在本文中，我们汇总了具有抗微生物活性的革兰氏阴性细菌天然产物的综合清单，包括其生物合成来源和（已知情况下）分子靶标的信息。我们还详细讨论了革兰氏阴性细菌中几种用于抗生素生物合成的不寻常途径，以突出该组微生物的非凡生物催化能力。
